ESP welcomes all delegates to the 36th European Congress of Pathology - either on-site in Florence or online. We look forward to exciting days filled with excellent scientific content. Please click on the below banner to access the congress portal to view the available industry symposia live.
 

Monday, 9 September 2024

Breakfast, 07:15-08:15

• BRS-02 | Eli Lilly | Spadolini 6
  Power hour: the importance of pathologists for the success of clinical studies
  001 | Lorenzo Gerratana | Welcome and introduction
  002 | Lorenzo Gerratana | Introduction into clinical study management
  003 | Giancarlo Pruneri | Biomarker testing in clinical trials
  004 | Albrecht Stenzinger | IVDR requirements for clinical studies
  005 |  Lorenzo Gerratana | Q&A and Round-table discussion
  006 | Albrecht Stenzinger | Summary and close
• BRS-03 | Roche | Spadolini 7
  Improving the diagnosis of B Cell lymphomas in routine pathology practice: advances in clonality evaluation
  001 | Teresa Marafioti & Marta Cañamero | Improving the diagnosis of B Cell lymphomas in routine pathology practice: advances in clonality evaluation

Lunch, 13:00-14:30

• LS-08 | Roche Diagnostics + Johnson & Johnson | Spadolini 2
  Pathways to precision: practical strategies for optimizing diagnostic excellence
  001 | Angelo Paolo Dei Tos | Introduction: testing pathway and patient leakage points
  002 | Deniz Nart | Precision oncology in lung cancer: enhancing patient outcomes through NGS and biomarker driven therapies - Ege University experience
  003 | Sylvie Lantuejoul | Optimizing the workflow to reduce failure rates
  004 | Isabelle Vanden Bempt | RNA-Based sequencing for simultaneous detection of clinically actionable fusions and mutations in solid tumours
  005 | Angelo Paolo Dei Tos | Round table and Q&A
• LS-09 | AstraZeneca | Spadolini 3
  Exploring the expanding applications of ctDNA and pathway mutations in breast cancer diagnostics
  001 | Espen Walker | Welcome and introduction
  002 | Elena Guerini Rocco | The utility of ctDNA in breast cancer
  003 | Nicola Fusco | Emerging testing strategies for the optimization of patient profiling in HR+/HER2- breast cancer
  004 | Espen Walker | Closing remarks
• LS-10 | 3DHistech | Spadolini 4
  Digital Pathology, IHC and Cytology
  001 | Catarina Eloy | Postponing evolution: why are we choosing to ignore the need for a digital transformation in pathology?
  002 | Felix Offner | Experiences with the implementation of digital cytology with Datexim and 3DHistech in Feldkirch, Austria
  003 | Yukako Yagi | Digital IHC, digital microCT
• LS-11 | gsk | Spadolini 5
  Guiding clinical outcomes in gynaecological cancers with early and accurate biomarker testing, including case-based examples
  001 | Gian Franco Zannoni | Introduction to biomarker testing in gynaecological cancers
  002 | Josef Rüschoff | Biomarker testing in endometrial cancer: current status and key considerations
  003 | Vanda Salutari | Treatment options according to molecular classification in endometrial cancer: clinical perspective and case study
  004 | Gian Franco Zannoni | Panel discussion on biomarker testing in endometrial cancer
  005 | Isabelle Treilleux | Biomarker testing in ovarian cancer: focus on HRD and BRCA
  006 | Vanda Salutari | Impact of biomarker testing on patient outcomes in ovarian cancer: clinical perspective and case study
  007 | Gian Franco Zannoni | Panel discussion on biomarker testing in ovarian cancer
• LS-12 | Agilent Technologies | Spadolini 7
  Changing testing in gastric cancer: a practical review
  001 | Mar Iglesias | Welcome & focus
  002 | Manuel Rodriguez-Justo | Case 1: The critical role of preanalytics in the context of case referrals
  003 | Matteo Fassan | Case 2: Assessing case heterogeneity effectively: from number of biopsies to tumour staging
  004 | Mar Iglesias | Q&A and closing remarks

Tuesday, 10 September 2024

Lunch, 13:00-14:30

• LS-13 | Roche | Spadolini 2
  Precision diagnostics in ovarian cancer: traversing from testing to treatment
  001 | Michelle Shiller & Domenica Lorusso
• LS-14 | AstraZeneca | Spadolini 3
  NSCLC: the evolution and expansion of testing across the care continuum
  001 | Alexander Yarunin | Welcome and introduction
  002 | Giuseppe Perrone | Navigating the evolving NSCLC testing landscape: guidance for the detection of driver and acquired resistance mutations
  003 | Nicola Normanno | Plasma ctDNA testing in lung cancer: application across the care continuum
  004 | Elena Guerini Rocco | Evaluating pathological complete response
  005 | Alexander Yarunin | Closing remarks
• LS-15 | Astellas | Spadolini 4
  The Pathologist's loom: weaving CLDN18.2 into practice
  001 | Matteo Fassan | Welcome and introductions
  002 | Lorenzo Fornaro | Unravelling the gastric cancer and GEJ tapestry: clinical insights into the current treatment landscape and emerging biomarkers
  003 | Philippe Taniere | Stitching the narrative: CLDN18.2 in the fabric of G/GEJ adenocarcinoma
  004 | Matteo Fassan | The Pathologist’s canvas: exploring CLDN18.2 expression patterns in G/GEJ adenocarcinoma
  005 | Matteo Fassan | Q&A session
  006 | Matteo Fassan | Summary and close

• LS-16 | Illumina | Spadolini 5
  Illumina's journey in precision pathology: from targeted panels to whole genome sequencing
  001 | Giancarlo Pruneri | Empowering precision pathology: genomic tools
  002 | Giulia Cangi | Enhancing precision: leveraging small panels for oncology testing
  003 | Sergio Villatoro | Maximizing insights: comprehensive genomic profiling
  004 | Greg Elgar | Charting the future of precision pathology: whole genome sequencing strategies
  005 | Giancarlo Pruneri | Unveiling the potential: panel discussion on the future of precision pathology
• LS-17 | Amgen | Spadolini 6
  The future of pathology: liquid biopsy, novel biomarkers, and tumour-agnostic therapies
  001 | Frédérique Penault-Llorca | Welcome and introduction
  002 | Lukas Bubendorf | Liquid biopsy in NSCLC: a discourse on controversies and advancements
  003 | Irene Esposito | The next frontier: FGFR2b and CLDN18.2 as promising biomarkers for G/GEJ cancers
  004 | Albrecht Stenzinger | Unlocking the power of MTAP-homozygous deletion: a tumour-agnostic biomarker
  005 | Frédérique Penault-Llorca | Panel discussion and Q&A
  006 | Frédérique Penault-Llorca | Summary and close
• LS-18 | Agilent Technologies | Spadolini 7
  How can scalable, open digital pathology solutions advance diagnostic quality and efficiency in pathology practice?
  001 | Jake Eden | Welcome & Agilent digital pathology focus
  002 | Robert D. Goldin | Digitising liver pathology: from research to clinical delivery
  003 | Teemu Tolonen | Multi-site, multi-AI pathology: quality, efficiency, and lead-time impact through scaled algorithm deployment
  004 | Bert Van Der Vegt | Integration of computational pathology algorithms in the clinical digital pathology workflow: connecting the dots
  005 | Holger Moch | Evolving role of digital pathology in anatomic and molecular pathology laboratories
  006 | Douglas Clark| Panel discussion

• Siemens Healthineers AG | 9 September 2024, 09:30-09:50, HotSpot stage at exhibition area
  Navigating the galaxy of data: a journey through digital pathology
  Dr. Svenja Lippok, Germany

• SOPHiA GENETICS | 9 September 2024, 10:00-10:20, HotSpot stage at exhibition area
  Building evidence and confidence in liquid biopsy solutions
  Dr. Alexander Yarunin, United Kingdom
  Verena Schramm, Germany
• SOPHiA GENETICS | 10 September 2024, 09:30-09:50, HotSpot stage at exhibition area
  Insights with impact: empowering laboratories with robust CGP solutions
  Verena Schramm, Germany
• Sysmex Europe SE | 10 September 2024, 10:00-10:20, HotSpot stage at exhibition area
  Liquid biopsy in breast cancer patient care
  Maria De Bonis, Italy
  Prof. Angelo Minucci, Italy

Roche (booth no. 15) will offer 6 Meet-the-Expert talks during the follwing times:

• Sunday, Sep 8, 13:10 - 13:30
  PIK3CA; Leveraging emerging insights to drive personalised care
  Dr. Nicola Fusco, Italy
• Sunday, Sep 8, 14:00-14:20
  The Roche Digital LightCycler: a real world performance evaluation in a Dutch hospital laboratory
  Dr. Wouter Pattje, USA
• Monday, Sep 9, 14:00-14:20
  Advancing precision medicine: PathAI and Roche Collaborate for AI-powered companion diagnostics
  Eric Walk, USA
  Michael Rivers, USA
• Monday, Sep 9, 13:10- 13:30
  Seamless integration of Ibex's AI algorithms within Roche's navify® Digital Pathology
  Michael Rivers, USA
  Stuart Shand, The Netherlands
• Monday, Sep 9, 16:40 - 17:00
  Unlock the power of in-house comprehensive genomic profiling with AVENIO Tumor Tissue CGP Kit V2 and the new foundation medicine HRD signature
  Robert Bulte, Switzerland
  Muriel De Vos, Switzerland
• Tuesday, Sep 10, 13:10 - 13:30
  Gastric cancer testing landscape in 2024 and beyond
  Mar Iglesias, Spain